Back to MPT Database

Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)

First-in-line, ultra-long-acting injectable MPT that offers durable and sustained protection from HIV transmission, high efficacy of contraception, increased user compliance, and the ability to be removed. It consists of a liquid MPT formulation utilizing excipients that form a biodegradable depot after subcutaneous injection (in-situ forming implant (ISFI)).

For more information, contact: S. Rahima Benhabbour, MSc., PhD at benhabs@email.unc.edu

Development Stage:

Preclinical – Early (Pre1)

Hormonal/Non-Hormonal:

Hormonal

Delivery Route & Method:

Systemic - Injectable In-situ Forming Implant (Subcutaneous)

Developer:

  • University of North Carolina, Chapel Hill

Funding:

  • Nat. Institute Allergy & Infect. Diseases (NIAID)
  • National Institutes of Health (NIH)

Funding Mechanism:

NIAID: R01

Past Funding:

NIAID

Back to MPT Database